Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific presents at BioStock Life Science Summit 2024

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for diseases with high unmet medical needs, today announced that the Company will present at BioStock Life Science Summit 2024, November 20, in Lund, Sweden. Sten R. Sörensen, CEO, will present Cereno Scientific to investors and potential partners.The Summit connects innovation and capital, providing small-to-medium cap Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level

First Product Utilizing Amferia Antimicrobial Technology Launched in Europe for Animal Wound Care

The Snögg BactiDefend Dressing, a new product in animal wound care using Amferia’s proprietary antimicrobial technology, has been launched for professional veterinary use across several European countries. The introduction of BactiDefend is the result of a partnership between Amferia and Orkla Wound Care, released under Orkla’s Snögg Animal Care brand. This collaboration aims to address the growing need for effective wound care and bacterial reduction in wounds of both small and large animals, especially in the light of increasing concerns over antibiotic-resistant infections.

Everfuel: Deputy CEO steps down to be nominated to the Board of Directors

Herning, Denmark, 30 October 2024 – Martin Skov Hansen will step down as deputy chief executive officer to qualify for nomination and appointment to the Board of Directors. Martin Skov Hansen, who joined Everfuel as Deputy CEO 1 January 2023, has been pivotal in the company's development. His focus on organisational development, HR, and maturing key business and internal processes has been instrumental in driving Everfuel forward. Prior to his Deputy CEO role, Martin served as member of the board in Everfuel, since the Company’s inception. Martin is expected to be nominated and

Outokumpu interim report January-September 2024 – Solid third-quarter adjusted EBITDA driven by business areas Europe and Ferrochrome

Outokumpu CorporationInterim reportOctober 30, 2024 at 9.00 am EETOutokumpu interim report January-September 2024 – Solid third-quarter adjusted EBITDA driven by business areas Europe and Ferrochrome Highlights in Q3 2024 · Stainless steel deliveries were 459,000 tonnes (449,000 tonnes)*. · Adjusted EBITDA amounted to EUR 86 million (EUR 51 million). · EBITDA was EUR 81 million (EUR 18 million). · ROCE amounted to -7.1% (5.3%). · Free cash flow was EUR -113 million (EUR -24 million incl. discontinued operations). · Earnings per share was EUR 0.05 (EUR -0.13). ·

Metso extends its digital portfolio with CathodeSense+ system for accurate cathode quality control

Metso Corporation’s press release on October 30, 2024, at 09:00 a.m. EETMetso is launching CathodeSense+ for fast and accurate quality analysis for high-capacity throughput, ensuring reliable results for all cathode stripping machines.  Developed for high-speed cathode stripping machines, Metso CathodeSense+ is a reliable free-standing system for the detection of nodules. Thanks to its advanced features, CathodeSense+ provides a full high-resolution 3D-scan, thus enabling higher cathode quality control.  “The new CathodeSense+ is an improved and more robust version of its predecessor.

Hemköp to open with Wallenstam in Årstaberg

In late 2026, Hemköp will open a new 1,300 square meter store in Wallenstam’s new construction in Årstaberg. Culinary pleasure and inspiration will be watchwords for the new store, which will offer all from carefully selected ingredients, local delicacies to well-prepared ready meals.This summer, Wallenstam started the construction of just over 400 new apartments in Årstaberg. A new construction that, in addition to apartments, will also provide a varied range of shops and services on the ground floor, and where Hemköp is planning to open its store in late 2026. “The store will have a

Kemira plans to close its manufacturing site in Vancouver, Canada

Kemira Oyj, Press Release, October 30, 2024 at 09.00 am EETKemira plans to close its manufacturing site in Vancouver, Canada   Kemira plans to consolidate some Pulp & Paper chemical production in North America, resulting in the closure of a manufacturing site in Vancouver, Canada. The Vancouver site produces process and functional chemicals for the Pulp & Paper segment. The planned consolidation is expected to impact approximately five employees.   It’s expected that production at the site will end during the first half of 2025 and will move to Kemira’s Washougal, Washington

New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference

Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still’s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still’s disease (AOSD) who had an inadequate response to high-dose glucocorticoids (GCs) will be presented at the American College of Rheumatology (ACR) Convergence in Washington D.C. The data were pooled from two open-label, single-arm interventional studies, the phase 3 NI-0501-14 study [EMERALD; NCT05001737 

The European Patent Office announces its Intention to grant Stayble’s patent for the treatment of disc herniation

Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the European Patent Office (EPO) has issued an "Intention to Grant" for the Company’s patent for the treatment of disc herniation with STA363. "Intention to Grant" means that only a formal process remains before Stayble can receive approved patents in countries affiliated with the EPO.The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides IP protection until 2040. Additionally, there is the possibility of applying for a five-year patent

Interim report July–September 2024

Third quarter · Revenue amounted to €527.8m (€440.5m), an increase of 19.8% with an organic growth of 17.4%. · Operating profit (EBIT) was €6.7m (€18.5m), representing an operating margin of 1.3% (4.2%), impacted by an impairment charge of €-16.4m. · Net result amounted to €-5.2m (€0.5m), which represents a margin of -1.0% (0.1%). · EBITDA was €73.9m (€64.8m), an increase of 14.1%. EBITDA margin was 14.0% (14.7%). · EBITDAaL amounted to €45.1m (€39.6m), an increase by 13.8%, corresponding to an EBITDAaL margin of 8.6% (9.0%). · Net cash flow from operating activities was

Fazer x Billebeino – combining quality and timelessness

The Blue moment of the autumn is characteristic for Fazer Blue milk chocolate. Blue is also the unifying factor between the iconic chocolate and the collaborative collection of Finnish streetwear brand Billebeino. The collection includes products for both women and men, and the products combine the distinctive elements of Fazer Blue with Billebeino's quality in a timelessly stylish way.Fazer Blue is not only an iconic and stylish, but also an always topical brand, much appreciated by Finns. One of the keys to its attractiveness is its ability to renew itself – even the beloved 100-year-old

Eevia Health Plc receives a 587 KSEK (51 KEUR) sales order for a Bilberry extract product

Eevia Health Plc ("Eevia" or "The Company") has received a 51 KEUR sales order from a European nutraceutical brand owner.The customer is a European brand owner headquartered in Sweden. The customer develops and markets effective herbal dietary supplements and cosmetics in over 50,000 pharmacies, health food shops, and other retail outlets across 38 countries, including China and the USA. This new order's sales value to Eevia is c. 51 KEUR for Feno-Myrtillus® 1, a bilberry extract standardized for anthocyanins. This is a repeat order and one of the few brand holders of Eevia services

Teleste: Interim report Q3 2024 will be published on 6 November, 2024 – Invitation to investor briefing

Teleste CorporationPress releaseOctober 30, 2024, at 8:30 a.m. EET TELESTE: INTERIM REPORT Q3 2024 WILL BE PUBLISHED ON 6 NOVEMBER - INVITATION TO INVESTOR BRIEFINGTeleste will publish its interim report 1 January – 30 September 2024 as a stock exchange release on 6 November approx. at 08:30 a.m. EET. A briefing for analysts, media, financial institutions and professional investors will be held virtually in Teams the same day at 09:30 a.m. EET hosted by CEO, Mr Esa Harju, CFO, Mrs Mervi Kerkelä-Hiltunen and interim CFO, Mr Tomi Närhinen.   PRESS BRIEFING (held in English):

Hotel Onyxen makes guests take notice: Guest well-being has never been more important

The boutique hotel in Gothenburg enhances the guest experience with a stronger focus on health and service. Guests now have the opportunity to borrow workout clothes during their stay, whether they choose to exercise in their rooms, go for a run, train outdoors, or use the award-winning Spa & Lifestyle Club, Hagabadet, where entry is included in their accommodation.Hotel Onyxen boasts a rich history and offers 34 stylishly decorated rooms, combining modern comfort with timeless charm. Located in the heart of Gothenburg, the hotel allows guests to enjoy the city’s vibrancy while also

Glaston’s interim report January–September 2024: Another solid quarter despite an uncertain environment

GLASTON CORPORATION                        INTERIM  REPORT            30.10.2024 AT 8.30This release is a summary of Glaston Corporation's January-September 2024 interim report. The complete report is attached to this release as a PDF file. The release is also available on the company's website at the address www.glaston.net. JULY–SEPTEMBER 2024 IN BRIEF · Orders received totaled EUR 52.8 (52.2) million · Net sales totaled EUR 55.4 (53.5) million · Comparable EBITA was EUR 4.2 (3.9) million, i.e. 7.5 (7.3)% of net sales · The operating result (EBIT) was EUR 2.2 (1.7)

Scandic’s interim report for the third quarter 2024 – Good quarter, stable bookings and capital returns to shareholders

Third quarter in summary, July 1 – September 30, 2024 · Net sales declined by 2.0 percent to 6,182 million SEK (6,307). Organic growth increased by 0.5 percent. · Average occupancy rate increased to 71.4 percent (71.0). · Average revenue per available room (RevPAR)increased to 941 SEK (933). · Operating profit totaled 1,155 million SEK (1,251). · Adjusted EBITDA was 1,077 million SEK (1,173). · Excluding IFRS 16, earnings per share equaled2.98 SEK (3.04). · Free cash flow was 659 million SEK (899). · Interest-bearing net debt/adjusted EBITDA amounted to 0.0x on

Notice of extraordinary general meeting of the shareholders in Readly International AB (publ) to be held on 25 November 2024

The shareholders of Readly International AB (publ), reg. no. 556912-9553, (the “Company” or “Readly”), are hereby called to an extraordinary general meeting to be held on Monday 25 November 2024 at 14.00 (CEST), at the Company’s head office at Gjörwellsgatan 30, 112 60 in Stockholm. Entry and registration begin at 13.30 (CEST).The board of directors has decided, pursuant to the Company’s articles of association, that shareholders shall have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the meeting by

Oriola Corporation’s Interim Report January-September 2024

Oriola Corporation Stock Exchange Release 30 October 2024 at 8.30 a.m. Oriola Corporation’s Interim Report January-September 2024 Improved profitability July-September 2024 highlights · Invoicing increased by 7.7 % to EUR 927.7 (861.7) million. · Net sales increased by 18.6% to EUR 424.4 (357.9) million. · Adjusted EBIT was EUR 5.5 (4.4) million. · EBIT was EUR 0.2 (-17.1) million and included adjusting items of EUR -5.3 (-21.6) million mainly related to the implementation costs of the ERP investment. · Profit for the period totalled EUR -1.9 (-20.2) million and

Nordic Paper Interim Report January - September 2024

QUARTERLY RESULTS JULY - SEPTEMBER · Net sales amounted to SEK 1,100 m (1,077 m), an increase of 2% compared with the same quarter the previous year. Excluding currency effects, net sales increased by 4%. · EBITDA amounted to SEK 106 m (108 m), representing an EBITDA margin of 9.6% (10.0%). · Operating profit amounted to SEK 67 m (69 m), representing an operating margin of 6.1% (6.4%). · Profit for the period amounted to SEK 32 m (34 m) and earnings per share to SEK 0.47 (0.50). · Cash flow from operating activities was SEK 195 m (301 m). · Return on operating capital,

There are no items matching the current filter
There are no more items matching the current filter
Back to top